IPO Year: 2025
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2026 | Buy | Roth Capital | |
| 10/6/2025 | $27.00 | Buy | Stifel |
| 10/6/2025 | $78.00 | Overweight | Piper Sandler |
| 10/6/2025 | $34.00 | Outperform | Leerink Partners |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
Fastest customizable press release news feed in the world
Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on February 10, 2026, pursuant to the "inducement grant" exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Pazdera entering into employment with LB Pharmaceuticals. Dr. Pazdera received options to purchase 140,000 shares of LB Pharmaceuticals' common stock. The options carry
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced that it has entered into a securities purchase agreement to sell 3,306,571 shares of its common stock and pre-funded warrants to purchase up to 1,417,107 shares of its common stock to a select group of institutional investors in a private placement. The purchase price of each share of common stock is $21.17. The purchase price of each pre-funded warrant is $21.1699, which represents the per share purchase price for
Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral investigational small molecule, is a potent and selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a po
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. "We are delighted to welcome Minako to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Dr. Pazdera has broad expertise encompassing both financial and strateg
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice President, Corporate Affairs and Lindsay Beaupre, the new Senior Vice President of People and Culture of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on January 9, 2026, pursuant to the "inducement grant" exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Ms. Rose and Ms. Beaupre entering into employment with LB Pharmaceuticals. Ms. Rose an
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. "We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Ms. Rose has extensive experience in corporate communications, investor relations, and patient advocacy within the biopharma industry. Ms. Beaupre is a sea
NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that it has granted to Kaya Pai Panandiker, the new Chief Commercial Officer of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on December 10, 2025, pursuant to the "inducement grant" exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Ms. Pai Panandiker entering into employment with LB Pharmaceuticals. Ms. Pai Panandiker received an option to purchase 195,000 shares of LB Pharmaceuticals' commo
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced the Company has been included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets on December 22, 2025, as part of the 2025 Russell indexes reconstitution. "Inclusion in the Russell 2000 and Russell 3000 indices represents an important milestone following our recent initial public offering," said Heather Turner, Chief Executive Officer. "We are approaching initiation of key clinical trials of LB-102 in both schizophrenia and bipolar depression, a period of significant momentum for the Company.
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that Heather Turner, Chief Executive Officer, will present at the Piper Sandler 37th Annual Healthcare Conference in New York, NY on Wednesday, December 3, 2025, at 9:30 a.m. ET. A live webcast of the presentation will be available on the "Investors" page under the "Events" section of the Company's website at https://ir.lbpharma.us/investors/events/, where a replay of the webcast will be archived. About LB-102 LB-102 is a Phase 3-ready oral, small molecule and a methylated derivative of amisulpride. In early 2025, LB Pharmaceuticals announced positive
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
3 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
3 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
3 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Roth Capital initiated coverage of LB Pharmaceuticals with a rating of Buy
Stifel initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $27.00
Piper Sandler initiated coverage of LB Pharmaceuticals with a rating of Overweight and set a new price target of $78.00
Leerink Partners initiated coverage of LB Pharmaceuticals with a rating of Outperform and set a new price target of $34.00
SCHEDULE 13G/A - LB PHARMACEUTICALS INC (0001691082) (Subject)
8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
SCHEDULE 13G - LB PHARMACEUTICALS INC (0001691082) (Subject)
8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
10-Q - LB PHARMACEUTICALS INC (0001691082) (Filer)
8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
SCHEDULE 13G - LB PHARMACEUTICALS INC (0001691082) (Subject)
8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
424B4 - LB PHARMACEUTICALS INC (0001691082) (Filer)
Live Leadership Updates
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. "We are delighted to welcome Minako to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Dr. Pazdera has broad expertise encompassing both financial and strateg
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. "We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Ms. Rose has extensive experience in corporate communications, investor relations, and patient advocacy within the biopharma industry. Ms. Beaupre is a sea
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer. Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in launching and scaling global brands. "We are very pleased to welcome Kaya to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs. Throughout his career, Dr. Rawls has led or contributed to more than a dozen successful regulatory filings and product approvals in the United States, Europe, and Japan, with specific experience in neuropsychiatric diseases. "Dr. Rawls has a remarkable depth of regulatory expertise that will be instrumental as we advance LB-102 into a Phase 3 clinical trial in schizophrenia and a Phase 2 clinical trial in bipolar depression in 2026," said Heather Turner, Chief Execu